Business Wire

Buzz Aldrin, Elon Musk, Tony Fadell, Brian May, and all Apollo Astronauts Make Landings at STARMUS V to Round Out History’s Most-Impossible Science Festival

Share

In one of history’s great science gatherings, STARMUS V has collected a dizzying lineup of stars. On Monday, June 24th, Dr. Brian May, Hans Zimmer, Steve Vai, and Rick Wakeman serenaded The Stephen Hawking Medal Winners to a packed house at Samsung Hall. Winners Brian Eno, Todd Douglas Miller and Elon Musk, who graciously joined the festivities live from the Falcon Heavy launchpad, welcomed Buzz as a delightful surprise to STARMUS V attendees where he accepted the Stephen Hawking Medal for “lifetime achievement.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190701005940/en/

STARMUS V Opening Celebration and Stephen Hawking Medal, June 25th 2019 (Photo: Business Wire)

STARMUS V Opening Celebration and Stephen Hawking Medal, June 25th 2019 (Photo: Business Wire)

Among the science celebrities was famed-astronomer, and fellow board member Jill Tarter of The SETI Institute, who hosted several panels including the Stephen Hawking Medal Winners at an enthusiastic press conference with the APOLLO Astronauts: Charlie Duke, Rusty Schweickart, Al Worden, Harrison Schmidt, Walt Cunningham, and Buzz Aldrin. The President of Armenia, Dr. Armen Sarkissian, addressed the crowd at STARMUS along with European Commissioner, Carlos Moedas of Portugal.

Elon Musk joined the festival live from the launchpad of Falcon Heavy just hours before their historic launch; graciously thanking the STARMUS board for receiving the Stephen Hawking Medal and emphasizing the importance of its relationship to science itself. It was another unforgettable moment for festival-goers.

Signaling an important shift to applied technology, Tony Fadell, inventor of the iPod and Principal at Future Shape, took over Stephen Hawking’s chair at STARMUS which will expand the festival’s influence and awareness, globally. “Many of our everyday things like laptops and smartphone tech were initially developed for space programs. Today more powerful, smaller, lighter and much cheaper consumer technologies are being adopted by NASA, ESA, SpaceX, etc. This opens up vast data streams about our earth from space. If we get this right, we can strengthen our capabilities to tackle critical issues on Earth: climate change, deforestation, plastic gyres, etc. protecting Earth and putting a multi-planet species within reach.”

Other milestone achievements at STARMUS V included Dr. Brian May and Dave Eicher presenting their new book “MISSION MOOD 3D” and the Swiss premiere of APOLLO 11 by Todd Douglas Miller.

Garik Israelian, STARMUS co-founder, commented “We are overwhelmed by the magnitude of this experience. And grateful. Each year STARMUS grows with more awareness and recognition of how we help our planet. I can’t think of a better time, or more appropriate place in history, for this festival.”

The STARMUS V lineup included more Nobel laureates, astronomers and science visionaries than any festival in history - a week of groundbreaking presentations by the world’s top thinkers – and doers.

**STARMUS extends a special thanks for the amazing support from its title sponsors, Sir Michael Hintze at CQS, Kaspersky Labs and Omega.**

STARMUS V HONORED PARTNERS

OMEGA and The Stephen Hawking Medal:

OMEGA is a prestigious Swiss watchmaker and member of the Swatch Group Ltd. Since 1848, the brand has been synonymous with excellence, innovation, and precision, as well as a pioneering spirit, demonstrated by its achievements in sports timekeeping, the oceans, and space. In fact, since 1965, the OMEGA Speedmaster has been worn on each of NASA's manned missions including all six moon landings.

Kaspersky Lab:

Kaspersky Lab is a global cybersecurity company, which has been operating in the market for 21 years. Kaspersky Lab’s deep threat intelligence and security expertise are constantly transforming into next-generation security solutions and services to protect businesses, critical infrastructure, governments and consumers around the globe. The company’s comprehensive security portfolio includes leading endpoint protection and a number of specialized security solutions and services to fight sophisticated and evolving digital threats. Over 400 million users are protected by Kaspersky Lab technologies and we help 270,000 corporate clients protect what matters most to them. Learn more at www.kaspersky.com.

The STARMUS festival’s other supporters include the International Astronomical Union, CERN, the European Space Agency, and the European Southern Observatory.

CQS:

CQS is an investment management firm founded by Sir Michael Hintze in 1999. The Firm’s deep experience allows it to offer solutions for investors across a range of return objectives and risk appetites. CQS is an active asset manager with expertise across corporate capital structures including corporate credit, structured credit, asset backed securities, convertibles, loans and equities. It is committed to delivering performance and high levels of service to its investors.

CQS has offices in London, New York, Hong Kong and Sydney. Our investors include pension funds, insurance companies, sovereign wealth funds, funds of funds, endowments and foundations, and private banks. www.cqs.com

Contact information

Journalists and media should respond this week to:
Marco Larsen
CEO, PUBLIC NYC
marco@publicnewyorkcity.com

Melissa Iglesias
Account Executive, PUBLIC NYC
melissa@publicnewyorkcity.com

Joël Steiger
Account Executive, Compresso Media
joel.steiger@compresso.ch

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical Association12.11.2019 16:08:00 CETPress release

Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced the publication of results from the Phase 3 CLEAR Wisdom trial in the Journal of the American Medical Association (JAMA).1 Bempedoic acid is currently undergoing review for marketing authorisation by the European Medicines Agency (EMA) and by the United States Food and Drug Administration (FDA). CLEAR Wisdom, a Phase 3, double-blind, randomised trial, evaluated the efficacy, long-term safety and tolerability of bempedoic acid 180 mg versus placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolaemia (HeFH) inadequately controlled with current lipid-modifying therapies, added on to maximally-tolerated statin therapy, which may mean no statin at all.1 The JAMA publication includes results for the primary efficacy endpoint of low-density lipoprotein cholesterol (LDL-C) lowering at 12 weeks and key secondary endpoints of safety and tolerability over 52

 Vertex Confirms Northern Ireland Offer Accepted for Cystic Fibrosis Medicines12.11.2019 15:57:00 CETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that the Regional Pharmaceutical Procurement Service in Northern Ireland has accepted an offer for access to all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Northern Ireland ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will have access to ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations will have access to SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor. We will support the arrangements being put in place to ensure clinicians will be able to prescribe to el

Andersen Global Announces First Collaboration in Croatia12.11.2019 14:30:00 CETPress release

Andersen Global announced today that it signed a Collaboration Agreement with one of Croatia’s largest law firms, KALLAY & PARTNERS Ltd. The addition of the Zagreb-based firm establishes Andersen Global’s presence in the country and continues the expansion of the organization in the region. Founded in 2006, KALLAY & PARTNERS Ltd. is led by Founder and Office Managing Director Marko Kallay. Under his leadership, the firm provides both foreign and domestic clients with a broad range of legal services, including banking and finance, commercial and corporate law, dispute settlement, arbitration and mediation, labor law, and regulator relationships. “Our firm values commitment, transparency, reliability and providing clients with the best-in-class legal services, and these values align well with Andersen Global’s standards and vision,” said Marko. “This collaboration will allow us to take our client service to the next level and expand our footprint more broadly. We are excited to work clos

Report: The Delivery Economy Uncovering Misalignment In the Supply Chain12.11.2019 14:00:00 CETPress release

The rapid growth of the Delivery Economy — the pervasive sentiment in which customers expect low-cost, fast and highly transparent delivery of goods — is pressuring companies to quickly address structural supply chain challenges that make it difficult for them to meet increasing customer demands, according to a new report from project44, the global leader in advanced visibility for shippers and logistics service providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005320/en/ (Graphic: Business Wire) The new report from project44, “Aligning the Supply Chain In The Age Of The Delivery Economy,” is based on a blind survey of 300 supply chain professionals. It is the second in a series of reports examining the emergence and impact of the Delivery Economy. The report highlights key issues plaguing both B2B and B2C supply chains and preventing adoption of the organization-wide delivery strategies that will be critical t

Modern Governance 8.0: New Report from Stanford’s Rock Center and Diligent Institute Reveals Corporate Directors Are Less Shareholder-Centric and Success Is No Longer Defined Solely by Shareholder Returns12.11.2019 14:00:00 CETPress release

In a new report released today, Diligent Institute and the Rock Center for Corporate Governance at Stanford University found that board directors consider both shareholder and stakeholder needs when making strategic decisions – reinforcing a stakeholder movement that embraces modern governance. The report, “Stakeholders Take Center Stage: Director Views on Priorities and Society,” includes responses and interviews with nearly 200 directors of public and private corporations globally. According to the survey, a vast majority of corporate directors (89%) believe it is important or very important for their company to consider the interests of non-shareholder stakeholders – such as employees, local communities, and the general public – as they work to achieve business objectives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005426/en/ The findings of this report echo the sentiments of the recent Business Roundtable “Stat

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised12.11.2019 13:36:00 CETPress release

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes when initiated in people hospitalised for any type of acute heart failure event once they have been stabilised. The study will include participants both with and without type 2 diabetes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191112005650/en/ Heart failure is the leading cause of hospitalisation in Europe and the US, and half of people with heart failure are expected to die within five years of diagnosis.2,3 However, outcomes for patients after they have been hospitalised for heart failure are poor, with a 15 percent mortality and 30 percent readmission rate within 60 to 90 days of discharge from hospital.4 Initiating treatment in